Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Abstract

Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of acute exacerbations of chronic obstructive pulmonary disease. Treatment may involve a single dose of the active ingredient by oral administration.

1 . A method for the treatment of acute exacerbations of chronic obstructive pulmonary disease which comprises administering to a subject in need thereof orally an effective amount of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof. 
     
     
         2 . The method of  claim 1  wherein a single dose of 3-[5-amino-4-(3-cyano-benzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof is administered. 
     
     
         3 . The method of  claim 2  wherein the single dose comprises 50 to 100 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof. 
     
     
         4 . The method of  claim 2  wherein the single dose comprises 60 to 90 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof. 
     
     
         5 . The method of  claim 2  wherein the single dose comprises 75 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate or solvate thereof. 
     
     
         6 . The method of  claim 2  wherein the single dose comprises 75 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide in its free form. 
     
     
         7 . The method of  claim 1  wherein said 3-[5-amino-4-(3-cyano-benzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt thereof is administered to said subject. 
     
     
         8 . The method of  claim 7  wherein 50 to 100 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt thereof is administered to said subject. 
     
     
         9 . The method of  claim 8  wherein 60 to 90 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt-thereof is administered to said subject. 
     
     
         10 . The method of  claim 9  wherein 75 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt thereof is administered to said subject. 
     
     
         11 . The method of  claim 9  wherein 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide is in its free form. 
     
     
         12 . The method of  claim 3  wherein the oral dosage form is a tablet. 
     
     
         13 . The method of  claim 11  wherein the oral dosage form is a tablet. 
     
     
         14 . The method of  claim 3  further comprising the administration of a therapeutically effective amount of prednisone. 
     
     
         15 . The method of  claim 14 , wherein 40 mg prednisone is administered orally once a day for 10 days. 
     
     
         16 . The method of  claim 14 , wherein 50 to 100 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt thereof is administered to said subject. 
     
     
         17 . The method of  claim 16 , wherein 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide is in its free form.